Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[2] It is manufactured by Shire plc.
Clinical data | |
---|---|
Trade names | Vpriv |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | N/A |
Elimination half-life | Plasma: 5–12 minutes (absorbed by macrophages) |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C2532H3850N672O711S16 |
Molar mass | 55593.61 g·mol−1 |
(what is this?) (verify) |
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.[3]
Velaglucerase alfa was approved for medical use in the United States in February 2010,[4][5] and in the European Union in August 2010.[3]
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[3][1]